Biolex Therapeutics raises $30M for multiple-sclerosis treatment
Biolex Therapeutics, a Pittsboro, N.C., developer of technology for improving the properties of monoclonal antibodies, raised $30 million in a third funding round.
Biolex specializes in producing proteins that are difficult to make with existing bioengineering processes and in optimizing the biological properties of monoclonal antibodies. It is also pursuing its own experimental drug candidates, and said the proceeds of this round will serve primarily to advance Locteron, an experimental time-release form of interferon alfa, into late-stage human tests against hepatitis C.
Investor Growth Capital led the round, joined by two other new investors, JP Morgan Securities and Easton Capital. Existing shareholders including Quaker BioVentures, Polaris Venture Partners, Intersouth Partners, Mitsui & Co. Venture Partners, Johnson & Johnson Development Corporation and Dow Venture Capital also participated. The company’s release is here (PDF).
Next Story: Helicos BioSciences lowers IPO price, raises $48.6M, then sags further
Previous Story: Radian6 raises $4M to monitor viral behavior in social media
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.